About Us
CSPC INNOVATION PHARMACEUTICAL CO.,LTD
CSPC Innovation Pharmaceutical Co., Ltd. (stock code：300765.SZ) is a subsidiary of CSPC Pharmaceutical Group (stock code：1093.HK), a constituent stock of the Hang Seng Index in Hong Kong. It has now developed into an innovative company integrating biopharmaceuticals, active pharmaceutical ingredients, and functional foods.
-
-
-
Biopharmaceutical field
CSPC Innovation relying on an advanced technology platform for innovative drug research and development, has made breakthroughs in cutting-edge biopharmaceutical areas such as antibody drugs, antibody-drug conjugates (ADCs), and mRNA vaccines. It has already launched China's first mRNA vaccine, the country's first biosimilar of Xolair® (Omalizumab for Injection) developed under Class 3.3 therapeutic biological products, as well as the Class 1 new biological drug PD-1 inhibitor Enshuxing®.
-
-
-
-
Functional ingredients and APIs
CSPC Innovation’s product line primarily includes caffeine, acarbose, anhydrous glucose raw materials, as well as Guoweikang vitamin C tablets and B-complex vitamin tablets. Among them, CSPC's caffeine production scale and market share are among the top globally, serving as a global supplier for the three major international beverage companies: Pepsi, Coca-Cola, and Red Bull. The company is also in the first tier of China's health food industry, having created the popular vitamin C tablet brand Guoweikang, loved by consumers.
-
At present, CSPC Innovation has gained recognition in the global market. Its products have received certifications such as GMP, ISO system, BRC, and KOSHER. Backed by a well-established overseas sales network, the company maintains a diversified presence in markets across North America, South America, Europe, and South Asia, with products distributed to numerous countries and regions worldwide. At the same time, the company has established a sustainable development management system and actively advances initiatives related to carbon inventory, carbon verification, and carbon footprint. It has also received a Silver rating from the Ecovadis evaluation system.
As an innovation-driven company, CSPC Innovation will continue to uphold R&D as its core engine in the future. With biopharmaceuticals and functional foods (ingredients) as its dual pillars, the company will deepen its presence in the healthcare industry, strive to enhance the international core competitiveness of China's biopharmaceutical industry, and contribute to the overall improvement of national health.
CSPC Innovative Pharmaceutical Co., Ltd.
Key Member—CSPC Megalith Biopharmaceutical Co., Ltd.
Key Member—CSPC SHENGXUE GLUCOSE CO., LTD.
Key Member—CSPC ZHONGNUO PHARMACEUTICAL (TAIZHOU) CO., LTD.
-
- CSPC Innovative Pharmaceutical Co., Ltd.
-
CSPC Innovation focuses on the R&D, production and commercialization of biopharmaceuticals, functional raw materials and health‑food products. Leveraging its large‑scale, standardized production system and rigorous quality control system, it continuously consolidates its competitive edge in the global functional raw materials market. Meanwhile, it is accelerating its transformation into an innovative biopharmaceutical enterprise, with strategic focus on cutting‑edge technology platforms including antibody drugs, ADCs and mRNA vaccines, and steadily advancing the R&D and industrialization of its biopharmaceutical pipeline.
-
- Key Member—CSPC Megalith Biopharmaceutical Co., Ltd.
-
CSPC Megalith Biopharmaceutical Co., Ltd. was founded in 2019 and is located in Shijiazhuang International Biomedical Industry Park. In accordance with international high standards, the company has built a high-tech industrialization base for innovative biopharmaceuticals with independent intellectual property rights.
-
- Key Member—CSPC SHENGXUE GLUCOSE CO., LTD.
-
Founded in 1991, the company is a wholly-owned subsidiary of CSPC Pharmaceutical Group. It has two manufacturing campuses (north and south) covering a total area of approximately 84,666.7 square meters (127 Chinese mu), and mainly produces a series of products including acarbose and anhydrous glucose. It currently has over 500 employees.
-
- Key Member—CSPC ZHONGNUO PHARMACEUTICAL (TAIZHOU) CO., LTD.
-
The factory area of Zhongnuo Taizhou Company covers a total area of 115,533.3 square meters (equivalent to 173.3 Chinese mu). It is planned to include 1 comprehensive office building, 1 GSP-compliant warehouse, 1 high-rise automated warehouse, 1 power workshop and 5 production workshops, with a total planned construction area of approximately 140,000 square meters.